Intrathecal Transplantation of UC-MSC in Patients With Early Stage of Chronic Spinal Cord Injury
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study aim to evaluate the safety and efficacy of intrathecal transplantation of
allogeneic umbilical cord derived mesenchymal stem cells (UC-MSC) for treatment of different
phrases of spinal cord injury. Here, the history of spinal cord injury is divided into three
periods, Sub-acute SCI, Early stage of chronic SCI, and Late stage of chronic SCI, which is
2W-2M, 2M-12M, and more than 12M after injury, respectively. The purpose is to investigate
whether the patients with spinal cord injury benefit from UC-MSC transplantation, and then
find out the best time for SCI treatment.
In this part of the study, the investigators will treat patients with early stage of chronic
spinal cord injury with UC-MSC transplantation or placebo.